알파 지중해빈혈 - 시장 인사이트, 역학 및 시장 예측(2036년)

Key Highlights:

• The Alpha Thalassemia Market is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan).
• The leading Alpha Thalassemia Companies, such as Agios Pharmaceuticals, Forma Therapeutics, Silence Therapeutics, and others.

Alpha Thalassemia Market and Epidemiology Analysis

• Alpha thalassemia is the most common non-sickle hemoglobinopathy in California, and Hb H represents over 80% of these cases.
• Treatment for alpha-thalassemia depends on disease severity and includes regular blood transfusions, iron chelation therapy to manage iron overload, and curative options like stem cell transplantation or gene therapy (not approved yet); milder cases may not require treatment, while newer targeted therapies are showing promising potential.
• Currently, there are no approved therapies for alpha thalassemia.
• The pipeline for alpha thalassemia is not very robust. However, some key players like Agios Pharmaceuticals (PYRUKYND), Novo Nordisk (etavopivat), Bristol-Myers Squibb (REBLOZYL), and others are conducting trials for the treatment of patients with alpha-thalassemia.
• In January 2025, Agios Pharmaceuticals announced that the US Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The review classification for this application is Standard, and the Prescription Drug User Fee Act (PDUFA) goal date is September 7, 2025.
• Awareness around alpha-thalassemia is steadily increasing, driven by advancements in diagnostics, improved management strategies, and the emergence of curative approaches such as stem cell and gene therapy. With ongoing innovation in targeted treatments, enhanced patient monitoring, and expanding newborn screening programs, the global outlook for alpha-thalassemia care is improving. As a result, the alpha-thalassemia treatment market is expected to witness significant growth in the coming years, supported by rising demand for effective therapies and broader healthcare access.

DelveInsight's "Alpha-thalassemia Treatment Market Insight, Epidemiology and Market Forecast - 2036" report delivers an in-depth analysis of a-thalassemia epidemiology, market, and clinical development in a-thalassemia. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the a-thalassemia market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The Alpha Thalassemia Treatment Market Report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted a-thalassemia market size from 2022 to 2036 in 7MM. The report also covers current alpha-thalassemia treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Factors Impacting the Alpha Thalassemia Market Growth

• Rising Prevalence of Alpha Thalassemia

The growing global burden of alpha thalassemia, particularly in regions such as Southeast Asia, the Middle East, and parts of Africa, is one of the key market drivers. With an increasing number of diagnosed cases, the demand for effective therapies, improved diagnostics, and supportive care is expanding, thereby fueling growth in the alpha thalassemia treatment market.

• Advances in Genetic Testing and Diagnostics

Technological improvements in molecular diagnostics, next-generation sequencing (NGS), and genetic testing are enhancing early detection rates for alpha thalassemia. Early diagnosis not only helps in effective patient management but also drives the demand for advanced therapeutic solutions, creating positive momentum for market growth.

• Growing Focus on Gene and Cell Therapies

The development of innovative therapies, including gene editing technologies such as CRISPR and stem cell-based treatments, is a major driver for the alpha thalassemia market. As clinical trials for curative therapies progress, patient and physician interest in these advanced treatment modalities is expected to significantly drive future market demand.

Alpha-thalassemia Disease Understanding

Alpha-thalassemia Overview

Alpha thalassemia is a hereditary disorder of the blood in which the body produces too little, or none, of the alpha-globin chains needed to form normal hemoglobin. The genes responsible for alpha-globin lie on chromosome 16, and each person normally has four copies (two HBA1 and two HBA2). The severity of the condition depends on how many of these gene copies are damaged or missing.

The condition is most common in parts of the world where malaria has been widespread, including Southeast Asia, the Mediterranean, Africa, and the Middle East, as carrying certain forms can offer some protection against the disease. Clinically, alpha thalassemia appears in four main forms: silent carrier status (loss of 1 gene), alpha-thalassemia trait (loss of 2 genes), Hemoglobin H disease (loss of 3 genes), and Hemoglobin Bart's hydrops fetalis (loss of all 4 genes), the last of which is typically fatal before or shortly after birth.

Alpha-thalassemia Diagnosis

"Evaluation for alpha-thalassemia typically starts by finding hypochromic, microcytic red blood cells in both parents, along with normal hemoglobin A2 levels, which helps differentiate it from beta-thalassemia. Iron deficiency should also be ruled out. Definitive diagnosis relies on DNA testing to identify a-thalassemia mutations, particularly when rapid results are available. Prenatal detection can be performed early through chorionic villus sampling, and fetal anemia can later be assessed by measuring the peak systolic velocity in the middle cerebral artery. In the United States, alpha-thalassemia is commonly first detected through newborn screening, followed by confirmatory studies such as a CBC, hemoglobin electrophoresis or HPLC, and genetic testing.

Alpha-thalassemia Treatment

Management of alpha thalassemia varies with how severe the condition is. People who are simply carriers usually don't need any medical intervention. Those with hemoglobin H disease might need blood transfusions from time to time, especially during infections or episodes of significant anemia. The most severe form, such as hydrops fetalis, requires ongoing transfusions along with iron-chelation therapy to prevent excess iron buildup. Although stem cell transplantation can be curative, it is uncommon due to the difficulty of finding suitable donors. New approaches-including gene therapy and methods to increase fetal hemoglobin-are being studied as potential long-term treatments.

Alpha-thalassemia Epidemiology

The alpha-thalassemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total diagnosed prevalent cases of thalassemia, total diagnosed prevalent cases of alpha-thalassemia, total diagnosed prevalent cases of alpha-thalassemia based on transfusion requirement, and total treated cases of alpha-thalassemia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2022 to 2036.

Key Findings from Alpha Thalassemia Epidemiological Analysis and Forecast

• About 300 million people around the world have the "thalassemia trait", which puts them at risk of having children with some form of thalassemia. More than 1 million people have non-transfusion-dependent thalassemia, while more than 100,000 people have transfusion-dependent thalassemia. In the US, there are at least 1,200 people with transfusion-dependent thalassemia.
• Worldwide, at least 300,000 children are born each year affected with a severe form of hemoglobinopathy. Furthermore, at least 20% of the global population carries at least a single gene deletion for alpha thalassemia.
• Roughly 56,000 children are born annually with severe alpha or beta thalassemia, of whom more than half require regular transfusions, and 5500 die perinatally due to alpha thalassemia major (hydrops fetalis).
• Over half of alpha-thalassemia cases in Japan are of Southeast Asian origin, while the rest involve unique, largely undetermined Japanese mutations, indicating a dual origin. Beta-thalassemia occurs in about 1 in 600-1,000 people, and alpha(+)-thalassemia (-a/) in about 1 in 400, making alpha-thal trait (-a/-a) extremely rare.

Alpha Thalassemia Epidemiology Segmentation

• Total diagnosed prevalent cases of thalassemia
• Total Alpha Thalassemia Diagnosed Prevalent Cases
• Total diagnosed prevalent cases of alpha-thalassemia based on transfusion requirement
• Total Alpha Thalassemia Treated Cases

Alpha-thalassemia Drug Analysis

The drug chapter segment of the Alpha Thalassemia Therapeutics Market Report encloses a detailed analysis of alpha-thalassemia late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into alpha thalassemia's pivotal clinical trial details, recent and expected market approvals, patent details, the latest Alpha Thalassemia news, and recent deals and collaborations.

Alpha Thalassemia Emerging Therapies

• PYRUKYND (mitapivat): Agios Pharmaceuticals

PYRUKYND, a pyruvate kinase activator, is approved in the US for treating hemolytic anemia in adults with pyruvate kinase deficiency and is authorized in the European Union for use in adult patients with the same condition. The US FDA has recently accepted a supplemental new drug application for mitapivat to treat adults with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

In June 2025, Agios Pharmaceuticals reported new findings on its pyruvate kinase activators, mitapivat and tebapivat, which are scheduled to be highlighted in oral and poster sessions at the European Hematology Association 30th Annual Congress in 2025.

• Etavopivat (FT-4202): Novo Nordisk

Etavopivat is a small-molecule compound that boosts the activity of the enzyme pyruvate kinase R (PKR). When PKR is activated, red blood cells generate more energy, causing levels of 2,3-DPG to fall. Lowering 2,3-DPG and increasing cellular energy are expected to help oxygen bind more tightly to defective hemoglobin, which in turn may keep red blood cells from assuming a sickled shape. This could extend their lifespan, lessen anemia, and decrease the frequency of VOCs. The drug is currently in Phase III trials for thalassemia, and according to the company's development pipeline, it remains in Phase II for the same condition.

Alpha Thalassemia Drug Market Insights

The market for alpha-thalassemia has gene therapies approved. However, no gene therapy is currently in the pipeline for alpha-thalassemia. Pyruvate kinase activators like PYRUKYND are emerging as promising oral therapies for both transfusion-dependent and non-transfusion-dependent alpha- and beta-thalassemia. Regulatory approvals are underway in key markets, including the US and EU.

Alpha-thalassemia Market Outlook

The alpha-thalassemia treatment landscape still relies heavily on routine blood transfusions and iron-chelation therapy to control anemia and prevent iron accumulation. Curative approaches, such as stem cell transplantation, remain constrained because suitable donors are scarce. While no drugs are currently approved specifically for alpha-thalassemia, several therapies exist for beta-thalassemia-such as CASGEVY, ZYNTEGLO, and REBLOZYL-and emerging candidates like PYRUKYND are being developed to lessen transfusion needs and potentially change long-term care strategies. Companies including Agios Pharmaceuticals and Novo Nordisk, among others, are advancing investigational treatments at various clinical stages to explore their potential use in alpha-thalassemia.

Key Findings

• In June 2025, Agios Pharmaceuticals presented new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th EHA Congress 2025.
• In January 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for label expansion of Pyrukynd, its only marketed drug, for the treatment of thalassemia.

Alpha-thalassemia Drug Uptake

This section focuses on the uptake rate of potential Alpha Thalassemia drugs expected to be launched in the market during 2026-2036, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Alpha-thalassemia Pipeline Developmental Activities

The report provides insights into different therapeutic candidates in the Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Latest KOL Views on Alpha Thalassemia

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or alpha-thalassemia market trends.

Alpha Thalassemia Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Alpha Thalassemia Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Alpha Thalassemia Market Report

• The Alpha Thalassemia Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview of alpha-thalassemia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Even though management of patients happens by off-label therapies, novel drug development is an ongoing opportunity for patients in this disease group. Market, historical, and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach are included in the report, covering the 7MM drug outreach.
• The Alpha Thalassemia Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Alpha Thalassemia Drugs Market.

Alpha-thalassemia Market Report Insights

• Patient-based Alpha Thalassemia Market Forecasting
• Therapeutic Approaches
• Alpha-thalassemia Pipeline Analysis
• Alpha-thalassemia Market Size and Trends
• Existing and future Alpha Thalassemia Market Opportunity

Alpha-thalassemia Market Report Key Strengths

• 11-Year Alpha Thalassemia Market Forecast
• 7MM Coverage
• Alpha-thalassemia Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Alpha Thalassemia Market Forecast Assumptions

Alpha-thalassemia Market Report Assessment

• Current Alpha Thalassemia Treatment Practices
• Alpha Thalassemia Unmet Needs
• Alpha Thalassemia Pipeline Drugs Profiles
• Alpha Thalassemia Market Attractiveness
• Alpha Thalassemia Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Alpha Thalassemia Market

Alpha Thalassemia Market Insights

• What is the historical and forecasted alpha-thalassemia patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination of treatment approaches will have a significant impact on the alpha-thalassemia drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of alpha thalassemia?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• How many key players are developing therapies for alpha thalassemia?
• Which drug will be the major contributor alpha thalassemia market by 2036?

Reasons to Buy the Alpha Thalassemia Market Report

• The Alpha Thalassemia Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the alpha thalassemia drugs market.
• Insights on patient burden/disease Alpha Thalassemia Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Alpha Thalassemia Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Alpha-thalassemia

4. Key Events of Alpha-thalassemia

5. Epidemiology and Market Methodology of Alpha-thalassemia

6. Alpha-thalassemia: Market Overview at a Glance

• 6.1. Total Market Share (%) Distribution of Alpha-thalassemia by Therapies in 2025
• 6.2. Total Market Share (%) Distribution of Alpha-thalassemia by Therapies in 2036

7. Disease Background and Overview: Alpha-thalassemia

• 7.1. Introduction
• 7.2. Risk Factors
• 7.3. Symptoms
• 7.4. Pathophysiology and disease pathways
• 7.5. Diagnostic Tests

8. Treatment and Guidelines

• 8.1. Current Treatment Landscape

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of Alpha-thalassemia in the 7MM
• 9.4. The United States
  • 9.4.1. Total Diagnosed Prevalent Cases of Thalassemia in the United States
  • 9.4.2. Total Diagnosed Prevalent Cases of Alpha-thalassemia in the United States
  • 9.4.3. Total Diagnosed Prevalent Cases of Alpha-thalassemia based on Transfusion Requirement in the United States
  • 9.4.4. Total Treatable Cases of Alpha-thalassemia in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Thalassemia in EU4 and the UK
  • 9.5.2. Total Diagnosed Prevalent Cases of Alpha-thalassemia in EU4 and the UK
  • 9.5.3. Total Diagnosed Prevalent Cases of Alpha-thalassemia based on Transfusion Requirement in EU4 and the UK
  • 9.5.4. Total Treatable Cases of Alpha-thalassemia in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Thalassemia in Japan
  • 9.6.2. Total Diagnosed Prevalent Cases of Alpha-thalassemia in Japan
  • 9.6.3. Total Diagnosed Prevalent Cases of Alpha-thalassemia based on Transfusion Requirement in Japan
  • 9.6.4. Total Treatable Cases of Alpha-thalassemia in Japan

10. Patient Journey of Alpha-thalassemia

12. Emerging Therapies of Alpha-thalassemia

• 12.1. Key Competitors
• 12.2. PYRUKYND (mitapivat): Agios Pharmaceuticals
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst views
• 12.3. Etavopivat (FT-4202): Novo Nordisk
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trial Information
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst Views

13. Alpha-thalassemia: Seven Major Market Size

• 13.1. Key Findings
• 13.2. Market Outlook of Alpha-thalassemia
• 13.3. Conjoint Analysis of Alpha-thalassemia
• 13.4. Key Market Forecast Assumptions of Alpha-thalassemia
  • 13.4.1. Cost Assumptions and Rebates
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of Alpha-thalassemia in the 7MM
• 13.6. United States
  • 13.6.1. Total Market Size of Alpha-thalassemia in the United States
  • 13.6.2. Total Market Size of Alpha-thalassemia by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of Alpha-thalassemia in EU4 and the UK
  • 13.7.2. Total Market Size of Alpha-thalassemia by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of Alpha-thalassemia in Japan
  • 13.8.2. Total Market Size of Alpha-thalassemia by Therapies in Japan

14. Unmet Needs of Alpha-thalassemia

15. SWOT Analysis of Alpha-thalassemia

16. KOL Views of Alpha-thalassemia

17. Market Access and Reimbursement of Alpha-thalassemia

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight